Studies show that 5080% of kidney transplant recipients become overweight or obese within five years, substantially raising the incidence of new cardiovascular events and shortening overall graft lifespan
Glucagon's Effects on Nerves: Glucagon receptors exist throughout the nervous system Activation affects nerve cell metabolism May alter nerve excitability or signal transmission Could disrupt normal sensory processing Supporting Evidence: Dysesthesia only occurs with retatrutide (which has glucagon component) Dose-dependent (higher glucagon activation = more dysesthesia) Not seen in Phase 2 at lower doses (less glucagon effect) Theory 2: Rapid Weight Loss and Nerve Changes Retatrutide produces the fastest, most substantial weight loss of any obesity medication 28.7% at 68 weeks (TRIUMPH-4) and 28.3% at 80 weeks (TRIUMPH-1)
GBD Chronic Kidney Disease Collaboration
May your ketones stay optimal, your muscle mass stay protected, and your weight loss stay permanent.
Age, activity level, and baseline metabolism also inform dosing decisions
Regardless of injection time, evidence-based management strategies include eating smaller, more frequent meals